For Ps & For PsA
1 injection, 4 times a year
after week 0 and week 4 injections1
For Ps & For PsA
Reliable 3-MONTH DOSING1
ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION AT:
Initiation
WEEK 0
WEEK 4
Month 3
WEEK 16
Month 6
WEEK 28
Month 9
WEEK 40
Month 12
WEEK 52
FLEXIBILITY to choose between the 150 mg/mL single-dose pen
or 150 mg/mL single-dose prefilled syringe
for in-office or at-home administration after proper training
regardless of baseline weight,
disease severity, or prior treatment
ADMINISTRATION Considerations
- SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1
- SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1
Dosing Considerations
SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1
SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1
Download OR EMAIL
DOSING CARD
INJECTION SUPPORT VIDEOS
Dosing Schedules
SKYRIZI is the only 4-dose-a-year biologic in psoriasis and psoriatic arthritis that offers a single-dose pen1
Ps DOSING SCHEDULES FOR SELECT BIOLOGICS FOR MODERATE TO SEVERE Ps1,3-8*
TREATMENT INITIATION
SKYRIZI® (risankizumab-rzaa)
Ps dosing: 150 mg subcutaneous injection; every 12 weeks after initiation
.
.
Initiation doses at Weeks 0 and 4
ILUMYA® (tildrakizumab-asmn)
Ps dosing: 100 mg subcutaneous injection; every 12 weeks after initiation
.
.
Initiation doses at Weeks 0 and 4
TREMFYA® (guselkumab)
Ps dosing: 100 mg subcutaneous injection; every 8 weeks after initiation
.
.
Initiation doses at Weeks 0 and 4
Taltz® (ixekizumab)
Ps dosing: 80 mg subcutaneous injection; every 4 weeks after initiation
.
.
.
.
.
.
.
160 mg (two 80 mg injections) at Week 0 followed by 80 mg every 2 weeks through Week 12
COSENTYX® (secukinumab)
Ps dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable
.
.
.
.
.
Once-weekly dosing for the first 5 doses
SILIQ® (brodalumab)
Ps Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation
.
.
.
Initiation doses at Weeks 0, 1, and 2
Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.
YEARLY DOSING† (AFTER INITIATION)
SKYRIZI® (risankizumab-rzaa)
Ps dosing: 150 mg subcutaneous injection; every 12 weeks after initiation
Every 12 Weeks
Total of 4 doses a year
.
.
.
.
ILUMYA® (tildrakizumab-asmn)
Ps dosing: 100 mg subcutaneous injection; every 12 weeks after initiation
Every 12 Weeks
Total of 4 doses a year
.
.
.
.
TREMFYA® (guselkumab)
Ps dosing: 100 mg subcutaneous injection; every 8 weeks after initiation
Every 8 Weeks
Total of 6 doses a year
.
.
.
.
.
.
Taltz® (ixekizumab)
Ps dosing: 80 mg subcutaneous injection; every 4 weeks after initiation
Every 4 Weeks
Total of 12 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
COSENTYX® (secukinumab)
Ps dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable
Every 4 Weeks
Total of 12 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
SILIQ® (brodalumab)
Ps Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation
Every 2 Weeks
Total of 24 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
HUMIRA® (adalimumab)
Ps dosing: 40 mg subcutaneous injection every other week
Every 2 Weeks
Total of 24 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.
PsA DOSING SCHEDULES FOR SELECT BIOLOGICS FOR ADULTS WITH ACTIVE PsA1,4-7*
TREATMENT INITIATION
SKYRIZI® (risankizumab-rzaa)
PsA dosing: 150 mg subcutaneous injection; every 12 weeks after initiation
.
.
Initiation doses at Weeks 0 and 4
TREMFYA® (guselkumab)
PsA dosing: 100 mg subcutaneous injection; every 8 weeks after initiation
.
.
Initiation doses at Weeks 0 and 4
Taltz® (ixekizumab)
PsA recommended dosing: 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.
For patients with PsA and coexistent moderate-to-severe Ps, the dosing regimen for adult Ps should be used.
.
160 mg (two 80 mg injections) at Week 0
COSENTYX® (secukinumab)
PsA dosing: With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without a loading dosage: 150 mg every 4 weeks. If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks.
For patients with PsA and coexistent moderate to severe Ps, the dosing and administration recommendations for Ps should be used.
.
.
.
.
.
Option to dose once-weekly for the first 5 doses or not initiate doses
Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.
MAINTENANCE DOSING† (AFTER INITIATION)
SKYRIZI® (risankizumab-rzaa)
PsA dosing: 150 mg subcutaneous injection; every 12 weeks after initiation
Every 12 Weeks
Total of 4 doses a year
.
.
.
.
TREMFYA® (guselkumab)
PsA dosing: 100 mg subcutaneous injection; every 8 weeks after initiation
Every 8 Weeks
Total of 6 doses a year
.
.
.
.
.
.
Taltz® (ixekizumab)
PsA dosing: 80 mg subcutaneous injection; every 4 weeks after initiation
Every 4 Weeks
Total of 12 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
COSENTYX® (secukinumab)
PsA dosing: With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without a loading dosage: 150 mg every 4 weeks
Every 4 Weeks
Total of 12 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
HUMIRA® (adalimumab)
PsA dosing: 40 mg subcutaneous injection every other week
Every 2 Weeks
Total of 24 doses a year
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.
INDICATIONS
SKYRIZI® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in adults.
ILUMYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.
Taltz® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.
COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.
SILIQ® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
HUMIRA® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis (Ps) and for adult patients with active psoriatic arthritis (PsA).
This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.
SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.1
Dosing schedules as of 1/25/2022.
*For IL-17is, IL-23is, and a TNF-alpha inhibitor.
†Based on doses required in each 48-week maintenance treatment period.
See Skyrizi Results in Ps
after 1 dose9
Enroll patients in SKYRIZI complete
Resources for your patients
Dosing schedules FOR IL-17 and IL-23 INHIBITORS1-6
asfaf
asfaf
asfaf
asfaf
asfaf
asfaf
This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.
*Based on doses required in each 48-week maintenance treatment period.
SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to inject 2 prefilled 75 mg syringes for the full 150 mg dose and to read the Instructions for Use before administration.
